Virbac SA Announces Consolidated Revenue Results for the Fourth Quarter and Year 2018
January 17, 2019 at 04:45 pm
Share
Virbac SA announced consolidated revenue results for the fourth quarter and year 2018. For the quarter, the company’s group revenue reached EUR 234.5 million in the fourth quarter, an increase of increase of 1.2% at real rates when compared to the same period in 2017. At comparable exchange rates, fourth quarter revenue shows moderate growth of increase of 1.8% (increase of 4.1% outside the United States). The quarter's growth is mainly driven by activity in Latin America, excluding Chile, which continues to benefit in particular from Brazil's double-digit growth, and by Asia, driven in particular by sustained activity in India and China.
For the year, the company’s revenue reached EUR 868.8 million compared with EUR 861.9 million over the same period in 2017, recording total growth of increase of 0.8%. Excluding the negative effect of exchange rates, notably the Indian rupee, the Brazilian real, the Australian and American dollar, revenue is growing at increase of 4.5%.
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.4%), Europe (26.2%), Latin America (17.1%), Asia (16.4%), North America (13.2%), Pacific (9.3%), Africa and Middle East (2.4%).